Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SCD | O00767 | 5/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871727 | 0.81 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL5871794 | 0.77 | OPRM1 (0.46) | HTR2CHTR2BSCDHTR1AHTR1D | |
| SCHEMBL5871303 | 0.75 | SCD (0.42) | HTR2AHTR2CHTR2BSCDCYP2D6 | |
| SCHEMBL5871167 | 0.75 | SCD (0.42) | HTR2CHTR2BSCDHTR1AHTR1D | |
| SCHEMBL5871065 | 0.71 | HTR1A (0.45) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871235 | 0.71 | HTR2A (0.48) | HTR2AHTR2CKCNH2 | |
| SCHEMBL5871930 | 0.70 | HTR1A (0.50) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871769 | 0.70 | HTR2C (0.58) | HTR2AHTR2CHTR2BTP53KCNH2 | |
| SCHEMBL5871593 | 0.69 | HTR1A (0.59) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871276 | 0.69 | HTR1A (0.47) | SCDHTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | claimed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | claimed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | HTR2A 209/4885HTR2C 222/4885HTR2B 91/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2A 143/4885HTR2C 107/4885HTR2B 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.